641:, placebo-controlled, randomized period during which they will receive lixivaptan or placebo for 12 months. This part of the trial will compare the change in estimated glomerular filtration rate (eGFR) measurements between the two groups to investigate the efficacy of lixivaptan in slowing the decline in kidney function. This is followed by Part 2 of the study, during which all study participants who complete Part 1 will receive lixivaptan in a single-arm, open-label phase for an additional 12 months. Part 2 will investigate whether lixivaptan's effect on kidney function continues to accrue over time. Altogether, including the titration periods, participants in the ACTION study will be taking study drug for more than two years, including lixivaptan for at least one year. It is expected that Part 1 will be completed for all participants by February 2025; Part 2 is projected to run until April 2026.
256:
233:
555:, a vasopressin antagonist in the same drug class as lixivaptan. In clinical studies, tolvaptan showed a significant decrease in the rate of disease progression in patients with ADPKD, which led to regulatory approvals for tolvaptan as a treatment of ADPKD in many countries, including the U.S., the EU, Japan, Canada, Australia, and Korea, among others. However, tolvaptan therapy is associated with potentially life-threatening
31:
413:) is an orally-active, non-peptide, selective vasopressin 2 receptor antagonist being developed as an investigational drug by Palladio Biosciences, Inc. (Palladio), a subsidiary of Centessa Pharmaceuticals plc. As of December 2021, lixivaptan is in Phase III clinical development for the treatment of
685:
that uses non-clinical and clinical drug data to predict whether a drug could cause idiosyncratic liver toxicity. DILIsym® replicated accurately the liver toxicity observed with tolvaptan in clinical studies. Conversely, results from the DILIsym® study with lixivaptan suggest that lixivaptan may be
665:
to an optimal dose, up to 50 patients with ADPKD will be enrolled and treated with lixivaptan for 52 weeks. They will be monitored frequently for signs of liver toxicity for as long as they are taking lixivaptan. At the completion of the 52 weeks maintenance period, patients will be eligible to
633:
of lixivaptan in patients with ADPKD. It is projected to enroll 1350 patients in more than 20 countries worldwide. If the ACTION study is successful, it will provide the main clinical evidence supporting the potential safety and efficacy of lixivaptan for the treatment of ADPKD.
686:
less likely to cause idiosyncratic liver toxicity within this modeling system. Whether this result reliably predicts a lower risk of liver injury for lixivaptan will require more clinical safety data, which will be collected as part of the two ongoing Phase III clinical studies.
620:
A Phase III study by
Palladio to investigate whether it is safe and effective for the treatment of ADPKD was commenced in October 2021. The Phase III program with lixivaptan consists of two ongoing clinical trials: the ACTION and ALERT studies.
525:
receptor antagonists have shown a reduction in kidney size and cyst volume in animal models of PKD. In particular, lixivaptan has demonstrated beneficial effects on cystic disease progression in rat and mouse models of ADPKD.
1457:
612:
Palladio conducted the ELiSA Phase II study with lixivaptan in 31 ADPKD patients. In this study, the proportion of study subjects who showed a urine osmolality response consistent with full vasopressin
1105:"Otsuka's JYNARQUE™ (tolvaptan) Approved by U.S. FDA as the First Treatment to Slow Kidney Function Decline in Adults at Risk of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD)"
1450:
1443:
43:
2203:
389:
637:
The ACTION trial consists of two main parts. In Part 1 of the study, after completing the screening, run-in and titration periods, study subjects will enter a two-arm,
373:
InChI=1S/C27H21ClFN3O2/c1-17-8-9-19(29)13-23(17)26(33)30-20-10-11-22(24(28)14-20)27(34)32-16-21-6-4-12-31(21)15-18-5-2-3-7-25(18)32/h2-14H,15-16H2,1H3,(H,30,33)
331:
414:
345:
1131:"Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database"
559:
in patients with ADPKD. Because of the risk of liver toxicity, in the US, tolvaptan is only available for ADPKD under a restricted distribution program (a
1392:"Comparison of the Hepatotoxic Potential of Two Treatments for Autosomal-Dominant Polycystic Kidney DiseaseUsing Quantitative Systems Toxicology Modeling"
1294:"Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors"
2208:
560:
497:
receptor antagonists may have utility as therapies for ADPKD. Genetic mutations associated with ADPKD cause an increase in intracellular levels of
2198:
505:
formation and expansion in the kidney. Cyst growth displaces and destroys normal kidney tissue, leading to a decreased number and function of
617:
receptor inhibition was qualitatively and quantitatively similar to the published effect seen in clinical studies conducted with tolvaptan.
855:
Gattone VH, Wang X, Harris PC, Torres VE (October 2003). "Inhibition of renal cystic disease development and progression by a vasopressin V
601:
1279:
for "Safety of
Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (ALERT)" at
653:
with lixivaptan is the ALERT study. The goal of this study is to investigate whether lixivaptan can be safely used in patients with
365:
1868:
1724:
1972:
1677:
446:
442:
67:
521:
receptor antagonists can restore normal levels of intracellular cAMP, thereby delaying cyst growth. Treatment with specific V
498:
1232:
Results of ELiSA, a Phase 2 Clinical Study with
Lixivaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
422:
172:
759:"Review and analysis of differing regulatory indications and expert panel guidelines for the treatment of hyponatremia"
212:
1261:
for "Efficacy and Safety of
Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ACTION)" at
418:
630:
141:
657:
who were previously treated with tolvaptan, but who had to permanently discontinue tolvaptan therapy due to
589:
1545:
1177:"Jynarque- tolvaptan kit Jynarque- tolvaptan tablet". DailyMed. March 31, 2020. Retrieved November 12, 2021
251:
514:
477:, or electrolyte free water excretion. This property of vaptans explains their use as therapies to treat
466:
201:
132:
1715:
1470:
908:
receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat"
462:
228:
1595:
682:
588:
sponsored by
Cardiokine, Inc. Across these studies, lixivaptan showed prolonged inhibition of the
87:
2041:
1952:
1947:
1803:
1798:
1055:
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, et al. (November 2017).
708:"Lixivaptan - an evidence-based review of its clinical potential in the treatment of hyponatremia"
1540:
1535:
1473:
1280:
1262:
1212:
1129:
Watkins PB, Lewis JH, Kaplowitz N, Alpers DH, Blais JD, Smotzer DM, et al. (November 2015).
1086:
884:
788:
2105:
2100:
2056:
1657:
1652:
1607:
1557:
1525:
1505:
1495:
2125:
1942:
1813:
1793:
1642:
1637:
1617:
1435:
1343:"The DILI-sim Initiative: Insights into Hepatotoxicity Mechanisms and Biomarker Interpretation"
1187:
Ku E, Nobakht N, Campese VM (May 2009). "Lixivaptan: a novel vasopressin receptor antagonist".
2144:
2120:
2115:
2110:
2076:
1962:
1858:
1481:
1466:
1421:
1372:
1323:
1204:
1160:
1078:
1037:
982:
929:
876:
837:
780:
739:
1927:
563:(REMS program). The FDA-approved prescribing information for tolvaptan for ADPKD includes a
2071:
1853:
1848:
1833:
1695:
1577:
1411:
1403:
1362:
1354:
1313:
1305:
1292:
Woodhead JL, Brock WJ, Roth SE, Shoaf SE, Brouwer KL, Church R, et al. (January 2017).
1196:
1150:
1142:
1068:
1027:
1017:
972:
964:
919:
868:
827:
819:
770:
729:
719:
597:
581:
268:
161:
96:
1622:
181:
1515:
650:
593:
255:
232:
2176:
2135:
1700:
1416:
1391:
1367:
1342:
1318:
1293:
1155:
1130:
1032:
1001:
977:
948:
832:
807:
734:
707:
658:
556:
604:(eGFR). Development of lixivaptan for hyponatremia indications is no longer ongoing.
2192:
2172:
564:
244:
1216:
1090:
888:
792:
30:
2016:
1986:
1902:
1882:
1758:
1104:
638:
585:
482:
121:
1275:
1257:
509:. Because intracellular cAMP is a secondary messenger for vasopressin acting at V
775:
758:
2168:
2021:
2006:
1991:
1932:
1907:
1897:
1887:
1823:
1763:
1753:
1748:
1738:
1510:
438:
426:
808:"Vasopressin and disruption of calcium signalling in polycystic kidney disease"
2095:
2061:
2051:
2036:
1937:
1843:
1788:
1783:
1682:
1572:
1500:
1407:
1200:
1146:
667:
307:
152:
2066:
2026:
2001:
1912:
1892:
1818:
1768:
1743:
1705:
1690:
1667:
1647:
1632:
1627:
1612:
1602:
1550:
1520:
1309:
1000:
Di Mise A, Wang X, Ye H, Pellegrini L, Torres VE, Valenti G (October 2021).
953:
Receptor
Antagonist on Polycystic Kidney Disease Development in a Rat Model"
678:
662:
580:
Lixivaptan was previously administered to more than 1600 subjects across 36
552:
478:
474:
1425:
1376:
1327:
1208:
1164:
1082:
1041:
1006:
R as therapeutic strategy for autosomal dominant polycystic kidney disease"
986:
933:
924:
903:
880:
841:
823:
784:
743:
22:
1073:
1056:
1022:
2011:
1838:
1778:
1672:
1590:
1567:
1530:
506:
2140:
1996:
1922:
1808:
1562:
1057:"Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease"
107:
1358:
968:
724:
473:
R) in kidney tubular epithelial cells, thereby having a net effect of
1828:
584:
as part of a prior clinical development program for the treatment of
192:
806:
Chebib FT, Sussman CR, Wang X, Harris PC, Torres VE (August 2015).
1002:"Pre-clinical evaluation of dual targeting of the GPCRs CaSR and V
872:
654:
548:
330:
321:
947:
Wang X, Constans MM, Chebib FT, Torres VE, Pellegrini L (2019).
502:
1439:
1390:
Woodhead JL, Pellegrini L, Shoda LK, Howell BA (January 2020).
501:(cAMP), which results in increased cellular proliferation and
78:- benzodiazepine-5-carbonyl)phenyl]-5-fluoro-2-methylbenzamide
217:
757:
Verbalis JG, Grossman A, Höybye C, Runkle I (July 2014).
681:
was studied in DILIsym®, a state of the art, multiscale
396:
353:
C1c2cccn2Cc3ccccc3N1C(=O)c4ccc(cc4Cl)NC(=O)c5cc(F)ccc5C
902:
Wang X, Gattone V, Harris PC, Torres VE (April 2005).
429:
designation to lixivaptan for the treatment of ADPKD.
629:
The ACTION study is a pivotal registration-enabling
2158:
2085:
1971:
1867:
1723:
1714:
1480:
319:
306:
267:
262:
243:
211:
191:
171:
151:
140:
131:
106:
86:
58:
42:
37:
120:
95:
1230:Shusterman NH, Hogan LC, Pellegrini L (2019).
701:
699:
551:has been demonstrated by clinical trials with
1451:
1236:Journal of the American Society of Nephrology
912:Journal of the American Society of Nephrology
8:
1234:. ASN Kidney Week 2019 Abstract supplement.
461:receptor antagonists inhibit the binding of
415:Autosomal dominant polycystic kidney disease
21:
1720:
1458:
1444:
1436:
1238:. Vol. 30. p. 339. Poster PO844.
254:
231:
160:
29:
2204:Drugs acting on the cardiovascular system
1415:
1366:
1317:
1251:
1249:
1247:
1245:
1154:
1072:
1031:
1021:
976:
923:
831:
774:
733:
723:
561:Risk Evaluation and Mitigation Strategies
180:
567:for the risk of serious liver toxicity.
1189:Expert Opinion on Investigational Drugs
695:
370:
350:
227:
72:
245:
20:
666:continue to receive lixivaptan in an
200:
7:
763:Current Medical Research and Opinion
602:estimated glomerular filtration rate
1061:The New England Journal of Medicine
111:
1347:Clinical and Translational Science
14:
417:(ADPKD), the most common form of
2209:Vasopressin receptor antagonists
291:
288:
285:
279:
904:"Effectiveness of vasopressin V
443:vasopressin receptor antagonist
378:Key:PPHTXRNHTVLQED-UHFFFAOYSA-N
2199:Drugs not assigned an ATC code
957:American Journal of Nephrology
547:receptor antagonists to treat
499:cyclic adenosine monophosphate
297:
273:
1:
706:Bowman BT, Rosner MH (2013).
539:Receptor Antagonists in ADPKD
776:10.1185/03007995.2014.920314
592:, as measured by changes in
423:Food and Drug Administration
661:. In the study, following
2225:
949:"Effect of a Vasopressin V
812:Nature Reviews. Nephrology
263:Chemical and physical data
2027:Vasotocin (argiprestocin)
2022:Vasopressin (argipressin)
1913:Vasotocin (argiprestocin)
1908:Vasopressin (argipressin)
1769:Vasotocin (argiprestocin)
1764:Vasopressin (argipressin)
1551:Vasotocin (argiprestocin)
1408:10.1007/s11095-019-2726-0
1341:Watkins PB (March 2019).
1201:10.1517/13543780902889760
1147:10.1007/s40264-015-0327-3
419:polycystic kidney disease
386:
361:
341:
63:
28:
631:Phase III clinical trial
445:. It is a member of the
437:Lixivaptan is a potent,
1396:Pharmaceutical Research
600:, plasma copeptin, and
590:vasopressin V2 receptor
543:Proof of efficacy for V
1943:ORG-52186 (SCH-740935)
1665:Catabolism inhibitors:
1298:Toxicological Sciences
1273:Clinical trial number
1255:Clinical trial number
925:10.1681/ASN.2004121090
859:receptor antagonist".
824:10.1038/nrneph.2015.39
515:vasopressin receptor 2
467:vasopressin receptor 2
1310:10.1093/toxsci/kfw193
1074:10.1056/NEJMoa1710030
1023:10.1096/fj.202100774R
1471:vasopressin receptor
1109:Otsuka press release
463:arginine vasopressin
1673:Bestatin (ubenimex)
683:computational model
674:DILIsym simulations
433:Mechanism of action
25:
1281:ClinicalTrials.gov
1263:ClinicalTrials.gov
425:(FDA) has granted
2186:
2185:
2166:Carrier proteins:
2154:
2153:
2145:lithium carbonate
2133:Other inhibitors:
1685:
1541:PF-06655075 (PF1)
1359:10.1111/cts.12629
1141:(11): 1103–1113.
1067:(20): 1930–1942.
969:10.1159/000500667
867:(10): 1323–1326.
725:10.2147/CE.S36744
670:extension study.
404:
403:
332:Interactive image
213:CompTox Dashboard
16:Chemical compound
2216:
1721:
1696:o-Phenanthroline
1683:
1460:
1453:
1446:
1437:
1430:
1429:
1419:
1387:
1381:
1380:
1370:
1338:
1332:
1331:
1321:
1289:
1283:
1271:
1265:
1253:
1240:
1239:
1227:
1221:
1220:
1184:
1178:
1175:
1169:
1168:
1158:
1126:
1120:
1119:
1117:
1115:
1101:
1095:
1094:
1076:
1052:
1046:
1045:
1035:
1025:
997:
991:
990:
980:
944:
938:
937:
927:
899:
893:
892:
852:
846:
845:
835:
803:
797:
796:
778:
769:(7): 1201–1207.
754:
748:
747:
737:
727:
703:
625:The ACTION study
598:urine osmolality
596:markers such as
582:clinical studies
571:Clinical studies
449:class of drugs.
400:
399:
392:
334:
314:
299:
293:
290:
287:
281:
275:
258:
247:
236:
235:
221:
219:
204:
184:
164:
144:
124:
114:
113:
99:
33:
26:
24:
2224:
2223:
2219:
2218:
2217:
2215:
2214:
2213:
2189:
2188:
2187:
2182:
2150:
2081:
1976:
1967:
1872:
1863:
1728:
1710:
1516:Lipo-oxytocin-1
1476:
1464:
1434:
1433:
1389:
1388:
1384:
1340:
1339:
1335:
1291:
1290:
1286:
1272:
1268:
1254:
1243:
1229:
1228:
1224:
1186:
1185:
1181:
1176:
1172:
1128:
1127:
1123:
1113:
1111:
1103:
1102:
1098:
1054:
1053:
1049:
1005:
999:
998:
994:
952:
946:
945:
941:
907:
901:
900:
896:
861:Nature Medicine
858:
854:
853:
849:
805:
804:
800:
756:
755:
751:
705:
704:
697:
692:
676:
651:Phase III study
647:
645:The ALERT study
627:
616:
610:
594:pharmacodynamic
578:
573:
546:
541:
538:
532:
524:
520:
512:
496:
491:
472:
460:
455:
435:
395:
393:
390:(what is this?)
387:
382:
379:
374:
369:
368:
357:
354:
349:
348:
337:
312:
302:
296:
284:
278:
239:
215:
207:
187:
167:
147:
127:
110:
102:
82:
79:
71:
70:
54:
17:
12:
11:
5:
2222:
2220:
2212:
2211:
2206:
2201:
2191:
2190:
2184:
2183:
2181:
2180:
2162:
2160:
2156:
2155:
2152:
2151:
2149:
2148:
2138:
2136:Demeclocycline
2129:
2128:
2123:
2118:
2113:
2108:
2103:
2098:
2089:
2087:
2083:
2082:
2080:
2079:
2074:
2069:
2064:
2059:
2054:
2049:
2044:
2039:
2030:
2029:
2024:
2019:
2014:
2009:
2004:
1999:
1994:
1989:
1980:
1978:
1974:
1969:
1968:
1966:
1965:
1956:
1955:
1950:
1945:
1940:
1935:
1930:
1925:
1916:
1915:
1910:
1905:
1900:
1895:
1890:
1885:
1876:
1874:
1870:
1865:
1864:
1862:
1861:
1856:
1851:
1846:
1841:
1836:
1831:
1826:
1821:
1816:
1811:
1806:
1801:
1796:
1791:
1786:
1781:
1772:
1771:
1766:
1761:
1756:
1751:
1746:
1741:
1732:
1730:
1726:
1718:
1712:
1711:
1709:
1708:
1703:
1701:Phosphoramidon
1698:
1693:
1688:
1680:
1675:
1670:
1661:
1660:
1655:
1650:
1645:
1640:
1635:
1630:
1625:
1620:
1615:
1610:
1605:
1593:
1581:
1580:
1575:
1570:
1565:
1560:
1548:
1543:
1538:
1533:
1528:
1523:
1518:
1513:
1508:
1503:
1498:
1486:
1484:
1478:
1477:
1465:
1463:
1462:
1455:
1448:
1440:
1432:
1431:
1382:
1353:(2): 122–129.
1333:
1284:
1266:
1241:
1222:
1195:(5): 657–662.
1179:
1170:
1121:
1096:
1047:
1016:(10): e21874.
1003:
992:
963:(6): 487–493.
950:
939:
918:(4): 846–851.
905:
894:
856:
847:
818:(8): 451–464.
798:
749:
694:
693:
691:
688:
675:
672:
659:liver toxicity
646:
643:
626:
623:
614:
609:
606:
577:
574:
572:
569:
557:liver toxicity
544:
540:
536:
533:
531:
528:
522:
518:
510:
494:
490:
487:
485:hyponatremia.
470:
458:
454:
451:
434:
431:
402:
401:
384:
383:
381:
380:
377:
375:
372:
364:
363:
362:
359:
358:
356:
355:
352:
344:
343:
342:
339:
338:
336:
335:
327:
325:
317:
316:
310:
304:
303:
300:
294:
282:
276:
271:
265:
264:
260:
259:
249:
241:
240:
238:
237:
229:DTXSID00168472
224:
222:
209:
208:
206:
205:
197:
195:
189:
188:
186:
185:
177:
175:
169:
168:
166:
165:
157:
155:
149:
148:
146:
145:
137:
135:
129:
128:
126:
125:
117:
115:
104:
103:
101:
100:
92:
90:
84:
83:
81:
80:
74:
66:
65:
64:
61:
60:
56:
55:
53:
52:
48:
46:
40:
39:
35:
34:
15:
13:
10:
9:
6:
4:
3:
2:
2221:
2210:
2207:
2205:
2202:
2200:
2197:
2196:
2194:
2178:
2174:
2170:
2167:
2164:
2163:
2161:
2157:
2146:
2142:
2139:
2137:
2134:
2131:
2130:
2127:
2124:
2122:
2119:
2117:
2114:
2112:
2109:
2107:
2104:
2102:
2099:
2097:
2094:
2091:
2090:
2088:
2084:
2078:
2075:
2073:
2070:
2068:
2065:
2063:
2060:
2058:
2055:
2053:
2050:
2048:
2045:
2043:
2040:
2038:
2035:
2032:
2031:
2028:
2025:
2023:
2020:
2018:
2015:
2013:
2010:
2008:
2005:
2003:
2000:
1998:
1995:
1993:
1990:
1988:
1985:
1982:
1981:
1979:
1977:
1970:
1964:
1961:
1958:
1957:
1954:
1951:
1949:
1946:
1944:
1941:
1939:
1936:
1934:
1931:
1929:
1926:
1924:
1921:
1918:
1917:
1914:
1911:
1909:
1906:
1904:
1901:
1899:
1896:
1894:
1891:
1889:
1886:
1884:
1881:
1878:
1877:
1875:
1873:
1866:
1860:
1857:
1855:
1852:
1850:
1847:
1845:
1842:
1840:
1837:
1835:
1832:
1830:
1827:
1825:
1822:
1820:
1817:
1815:
1812:
1810:
1807:
1805:
1802:
1800:
1797:
1795:
1792:
1790:
1787:
1785:
1782:
1780:
1777:
1774:
1773:
1770:
1767:
1765:
1762:
1760:
1757:
1755:
1752:
1750:
1747:
1745:
1742:
1740:
1737:
1734:
1733:
1731:
1729:
1722:
1719:
1717:
1713:
1707:
1704:
1702:
1699:
1697:
1694:
1692:
1689:
1687:
1681:
1679:
1676:
1674:
1671:
1669:
1666:
1663:
1662:
1659:
1656:
1654:
1651:
1649:
1646:
1644:
1641:
1639:
1636:
1634:
1631:
1629:
1626:
1624:
1621:
1619:
1616:
1614:
1611:
1609:
1606:
1604:
1601:
1597:
1596:Tocinoic acid
1594:
1592:
1589:
1586:
1583:
1582:
1579:
1576:
1574:
1571:
1569:
1566:
1564:
1561:
1559:
1556:
1552:
1549:
1547:
1544:
1542:
1539:
1537:
1534:
1532:
1529:
1527:
1524:
1522:
1519:
1517:
1514:
1512:
1509:
1507:
1504:
1502:
1499:
1497:
1494:
1491:
1488:
1487:
1485:
1483:
1479:
1475:
1472:
1468:
1461:
1456:
1454:
1449:
1447:
1442:
1441:
1438:
1427:
1423:
1418:
1413:
1409:
1405:
1401:
1397:
1393:
1386:
1383:
1378:
1374:
1369:
1364:
1360:
1356:
1352:
1348:
1344:
1337:
1334:
1329:
1325:
1320:
1315:
1311:
1307:
1303:
1299:
1295:
1288:
1285:
1282:
1278:
1277:
1270:
1267:
1264:
1260:
1259:
1252:
1250:
1248:
1246:
1242:
1237:
1233:
1226:
1223:
1218:
1214:
1210:
1206:
1202:
1198:
1194:
1190:
1183:
1180:
1174:
1171:
1166:
1162:
1157:
1152:
1148:
1144:
1140:
1136:
1132:
1125:
1122:
1110:
1106:
1100:
1097:
1092:
1088:
1084:
1080:
1075:
1070:
1066:
1062:
1058:
1051:
1048:
1043:
1039:
1034:
1029:
1024:
1019:
1015:
1011:
1010:FASEB Journal
1007:
996:
993:
988:
984:
979:
974:
970:
966:
962:
958:
954:
943:
940:
935:
931:
926:
921:
917:
913:
909:
898:
895:
890:
886:
882:
878:
874:
873:10.1038/nm935
870:
866:
862:
851:
848:
843:
839:
834:
829:
825:
821:
817:
813:
809:
802:
799:
794:
790:
786:
782:
777:
772:
768:
764:
760:
753:
750:
745:
741:
736:
731:
726:
721:
717:
713:
712:Core Evidence
709:
702:
700:
696:
689:
687:
684:
680:
673:
671:
669:
664:
660:
656:
652:
644:
642:
640:
635:
632:
624:
622:
618:
607:
605:
603:
599:
595:
591:
587:
583:
575:
570:
568:
566:
565:boxed warning
562:
558:
554:
550:
534:
529:
527:
516:
508:
504:
500:
488:
486:
484:
480:
476:
468:
464:
452:
450:
448:
444:
440:
432:
430:
428:
424:
420:
416:
412:
408:
398:
391:
385:
376:
371:
367:
360:
351:
347:
340:
333:
329:
328:
326:
323:
318:
311:
309:
305:
272:
270:
266:
261:
257:
253:
250:
248:
246:ECHA InfoCard
242:
234:
230:
226:
225:
223:
214:
210:
203:
199:
198:
196:
194:
190:
183:
179:
178:
176:
174:
170:
163:
159:
158:
156:
154:
150:
143:
139:
138:
136:
134:
130:
123:
119:
118:
116:
109:
105:
98:
94:
93:
91:
89:
85:
77:
73:
69:
62:
57:
50:
49:
47:
45:
41:
38:Clinical data
36:
32:
27:
19:
2165:
2132:
2093:Antagonists:
2092:
2046:
2042:JNJ-17079166
2034:Antagonists:
2033:
2017:Terlipressin
1987:Desmopressin
1983:
1959:
1953:TASP-0390325
1948:TASP-0233278
1920:Antagonists:
1919:
1903:Terlipressin
1883:Desmopressin
1879:
1804:JNJ-17308616
1799:JNJ-17079166
1776:Antagonists:
1775:
1759:Terlipressin
1735:
1664:
1600:Non-peptide:
1599:
1587:
1585:Antagonists:
1584:
1555:Non-peptide:
1554:
1492:
1489:
1399:
1395:
1385:
1350:
1346:
1336:
1304:(1): 61–74.
1301:
1297:
1287:
1274:
1269:
1256:
1235:
1231:
1225:
1192:
1188:
1182:
1173:
1138:
1134:
1124:
1114:November 12,
1112:. Retrieved
1108:
1099:
1064:
1060:
1050:
1013:
1009:
995:
960:
956:
942:
915:
911:
897:
864:
860:
850:
815:
811:
801:
766:
762:
752:
715:
711:
677:
648:
639:double-blind
636:
628:
619:
611:
586:hyponatremia
579:
576:Hyponatremia
542:
492:
483:hypervolemic
456:
453:Hyponatremia
441:, selective
436:
410:
406:
405:
394:
388:
75:
18:
2169:Neurophysin
2007:Ornipressin
1992:Felypressin
1933:Brezivaptan
1898:Ornipressin
1888:Felypressin
1824:Relcovaptan
1754:Selepressin
1749:Ornipressin
1739:Felypressin
1716:Vasopressin
1686:-Methionine
1536:PF-06478939
1511:Demoxytocin
1276:NCT04152837
1258:NCT04064346
1135:Drug Safety
649:The second
439:non-peptide
427:orphan drug
421:. The U.S.
315: g·mol
252:100.126.016
202:ChEMBL49429
97:168079-32-1
59:Identifiers
2193:Categories
2106:RWJ-339489
2101:Ribuvaptan
2096:Balovaptan
2062:Satavaptan
2057:RWJ-351647
2052:Mozavaptan
2047:Lixivaptan
2037:Conivaptan
1938:Nelivaptan
1844:WAY-267464
1789:Conivaptan
1784:Balovaptan
1658:WAY-162720
1653:SSR-126768
1608:Cligosiban
1573:WAY-267464
1526:Nacartocin
1506:Cargutocin
1501:Carbetocin
1496:Aspartocin
1474:modulators
690:References
668:open label
407:Lixivaptan
320:3D model (
308:Molar mass
182:8F5X4B082E
153:ChemSpider
133:IUPHAR/BPS
88:CAS Number
68:IUPAC name
23:Lixivaptan
2126:YM-222546
2067:Tolvaptan
2002:Lypressin
1984:Agonists:
1893:Lypressin
1880:Agonists:
1819:PF-184563
1814:LY-307174
1794:FR-218944
1744:Lypressin
1736:Agonists:
1706:Puromycin
1691:Leupeptin
1668:Amastatin
1648:Retosiban
1643:Nolasiban
1638:L-372,662
1633:L-371,257
1628:L-368,899
1618:Erlosiban
1613:Epelsiban
1603:Barusiban
1521:Merotocin
1490:Agonists:
1402:(2): 24.
718:: 47–56.
679:Tolvaptan
663:titration
553:tolvaptan
479:euvolemic
475:aquaresis
2121:VMAX-382
2116:VMAX-372
2111:VMAX-367
2086:Unsorted
2077:YM-35471
2012:TC OT 39
1963:TASP-699
1960:Ligands:
1859:YM-35471
1839:TC OT 39
1779:Atosiban
1591:Atosiban
1588:Peptide:
1568:TC OT 39
1531:Oxytocin
1493:Peptide:
1482:Oxytocin
1467:Oxytocin
1426:31909447
1377:30762301
1328:27655350
1217:72325634
1209:19379124
1165:26188764
1091:41483400
1083:29105594
1042:34486176
987:31117065
934:15728778
889:30926917
881:14502283
842:25870007
793:21539659
785:24809970
744:23874242
530:Research
507:nephrons
397:(verify)
44:ATC code
2141:Lithium
1997:LIT-001
1928:ABT-558
1923:ABT-436
1809:LIT-001
1563:LIT-001
1417:6944674
1368:6440570
1319:5216653
1156:4608984
1033:9290345
978:6647848
833:4539141
735:3712664
411:VPA-985
269:Formula
108:PubChem
2159:Others
2072:YM-471
1854:YM-471
1849:YM-218
1834:SRX251
1829:SRX246
1578:WJ0679
1424:
1414:
1375:
1365:
1326:
1316:
1215:
1207:
1163:
1153:
1089:
1081:
1040:
1030:
985:
975:
932:
887:
879:
840:
830:
791:
783:
742:
732:
447:vaptan
346:SMILES
313:473.93
193:ChEMBL
162:151067
122:172997
1623:IX-01
1213:S2CID
1087:S2CID
885:S2CID
789:S2CID
655:ADPKD
608:ADPKD
549:ADPKD
489:ADPKD
366:InChI
322:JSmol
1678:EDTA
1546:TGOT
1469:and
1422:PMID
1373:PMID
1324:PMID
1205:PMID
1161:PMID
1116:2021
1079:PMID
1038:PMID
983:PMID
930:PMID
877:PMID
838:PMID
781:PMID
740:PMID
517:), V
503:cyst
481:and
173:UNII
142:2238
51:none
1558:CA7
1412:PMC
1404:doi
1363:PMC
1355:doi
1314:PMC
1306:doi
1302:155
1197:doi
1151:PMC
1143:doi
1069:doi
1065:377
1028:PMC
1018:doi
973:PMC
965:doi
920:doi
869:doi
828:PMC
820:doi
771:doi
730:PMC
720:doi
513:R (
465:to
218:EPA
112:CID
2195::
2177:II
2175:,
1871:1B
1727:1A
1598:;
1553:;
1420:.
1410:.
1400:37
1398:.
1394:.
1371:.
1361:.
1351:12
1349:.
1345:.
1322:.
1312:.
1300:.
1296:.
1244:^
1211:.
1203:.
1193:18
1191:.
1159:.
1149:.
1139:38
1137:.
1133:.
1107:.
1085:.
1077:.
1063:.
1059:.
1036:.
1026:.
1014:35
1012:.
1008:.
981:.
971:.
961:49
959:.
955:.
928:.
916:16
914:.
910:.
883:.
875:.
863:.
836:.
826:.
816:11
814:.
810:.
787:.
779:.
767:30
765:.
761:.
738:.
728:.
714:.
710:.
698:^
469:(V
286:Cl
283:21
277:27
2179:)
2173:I
2171:(
2147:)
2143:(
1975:2
1973:V
1869:V
1725:V
1684:L
1459:e
1452:t
1445:v
1428:.
1406::
1379:.
1357::
1330:.
1308::
1219:.
1199::
1167:.
1145::
1118:.
1093:.
1071::
1044:.
1020::
1004:2
989:.
967::
951:2
936:.
922::
906:2
891:.
871::
865:9
857:2
844:.
822::
795:.
773::
746:.
722::
716:8
615:2
613:V
545:2
537:2
535:V
523:2
519:2
511:2
495:2
493:V
471:2
459:2
457:V
409:(
324:)
301:2
298:O
295:3
292:N
289:F
280:H
274:C
220:)
216:(
76:N
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
